which is involved in interactions between two receptors within the cell membrane, and an intracellular domain that contains the tyrosine kinase enzymatic activity. The EGFR autocrine pathway ...

A technology has been developed that can analyze tumor mutations in lung cancer patients to confirm drug resistance to ...

CURE® spoke with a lung cancer treatment expert about study findings showing survival benefits with the addition of ...

Targeted therapy revolutionized cancer treatment, with gene fusions leading the way when the FDA approved imatinib in 2001 to ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data for approved and ...

Novel macrocyclic heteroaryl derivatives acting as non-receptor tyrosine-protein kinase TYK2 and/or JAK1 and/or JAK2 inhibitors have been reported in a Hangzhou Highlightll Pharmaceutical Co. Ltd.

Discovered in-house by Eisai’s Tsukuba Research Laboratories, TASFYGO is an orally available novel tyrosine kinase inhibitor ...